Johnson and Johnson Newswire (Page 5)

Comprehensive Real-Time News Feed for Johnson and Johnson. (Page 5)

Results 81 - 100 of 12,614 in Johnson and Johnson

  1. How to Successfully Transition Your Church through New LeadershipRead the original story

    Wednesday Mar 25 | WFIL-AM Lafayette Hill

    Every week at Crosswalk, Dr. Barrier puts nearly 40 years of experience in the pastorate to work answering questions of doctrine or practice for laypeople, or giving advice on church leadership issues. Email him your questions at .


  2. KCG Consulting Launches New Website and Expanded ServicesRead the original story

    Wednesday Mar 25 | PRWeb

    Rich Kindberg and KCG consulting launched its new website and expanded service offerings to help provide businesses with greater focus for improved results. "We neither take a cookie cutter approach nor support an assignment with individuals who've never been in the trenches.


  3. DePuy Synthes launches TFNA System to improve outcomes in patients undergoing hip fracture surgeryRead the original story w/Photo

    Tuesday Mar 24 | Medical News

    DePuy Synthes Companies of Johnson & Johnson has launched the TFN-ADVANCED Proximal Femoral Nailing System , a nail, blade and screw system designed to improve patient outcomes by more closely matching the anatomy of patients undergoing hip fracture surgery. The TFNA System is featured this week by DePuy Synthes Trauma here at the 81st annual meeting of the American Academy of Orthopaedic Surgeons .


  4. Turmeric Curcumin: Prehistoric Roots, Modern ElixirRead the original story w/Photo

    Tuesday Mar 24 | CNN

    Several human and animal laboratory studies suggest that turmeric curcumin is a powerful anti-inflammatory and antioxidant compound. Interestingly, turmeric is a spice , food coloring and food preservative used in culinary and traditional Indian and Chinese medicine for thousands of years.


  5. Pharmacylics CEO: The $3.6 BILLION ManRead the original story w/Photo

    Tuesday Mar 24 | USA Today

    Robert Duggan, CEO of biotech drugmaker Pharmacyclics PCYC , will pocket over $3.5 billion from the company's sale to AbbVie ABBV , one of the biggest paydays ever from the buyout of a publicly held company. Under terms of the deal, Duggan will receive $3.55 billion for his 13.6 million shares, about an 18% stake in the biotech company, according to corporate filings.


  6. Tanezumab's Return Shows Pharma Has Held Its NerveRead the original story w/Photo

    Tuesday Mar 24 | Seeking Alpha

    Removal of a partial clinical hold on Pfizer and Lilly's tanezumab is the strongest sign yet of hope for the once-troubled anti-nerve growth factor ) drug class. When the partners begin a new round of trials to treat pain-related disorders, they should be neck and neck with Johnson & Johnson 's fulranumab in phase III.


  7. Retrofit Taps Key Healthcare Executive to Accelerate GrowthRead the original story w/Photo

    Tuesday Mar 24 | PRWeb

    Retrofit names leading industry executive Matthew Schoenthaler as Vice President of Sales and Account Management. He joins the recent high-talent hires at the comprehensive national weight management solution, signaling steady growth for the company as it makes aggressive moves into the corporate weight loss space.


  8. Gilead stock drops on hepatitis C drug's heart warningRead the original story w/Photo

    Tuesday Mar 24 | Business Journal

    Nine patients taking Gilead's Sovaldi or Harvoni for hepatitis C in addition to a drug to treat heart arrhythmias reported a slowing heartbeat. One patient died.


  9. New Report Available: Biocartis SA - Medical Equipment - Deals and Alliances ProfileRead the original story

    Tuesday Mar 24 |

    It focuses on providing personalized medicine for patients through its molecular diagnostics. The company undertakes the development of diagnostics technology platforms for multiplexed detection of bio-analytes, with oncology as its key focus area.


  10. Svelte Medical secures financing for ongoing operations, names new board memberRead the original story

    Tuesday Mar 24 |

    Svelte Medical Systems, Inc. said it has raised USD16 million in new capital with financing provided by the company's current investors, led by CNF Investments, the Gary and Mary West Health Investment fund and New Science Ventures. The company said it plans to use funding to support ongoing operations, expand infrastructure and commercialize the Svelte drug-eluting coronary stent-on-a-wire Integrated Delivery System and Rapid-Exchange platforms in Europe during the second half of 2015.


  11. Debate about contact-lens prices revives Florida's eye warsRead the original story w/Photo

    Tuesday Mar 24 | St. Petersburg Times

    Capitol insiders may have thought they'd seen the last of the eye wars, which for years were a perennial fight between optometrists and ophthalmologists over scope-of-practice issues. But a new twist, with new players, in the turf battle over eye care surfaced Monday in a debate about contact-lens prices that pitted a former Senate president against the current Senate majority leader.


  12. How Package Goods Companies Use Location to Market on MobileRead the original story w/Photo

    Tuesday Mar 24 | Street Fight

    The benefits of location data are obvious for retailers with physical storefronts, but can consumer packaged goods brands capitalize in similar ways? More and more, the answer is yes. Some of the largest CPG brands started to ramp up mobile spending last year as they look to influence an increasingly smartphone-wielding shopper.


  13. CymaBay Therapeutics Appoints Robert J. Wills, Ph.D. to Board of DirectorsRead the original story

    Tuesday Mar 24 | Freshnews

    CymaBay Therapeutics, Inc. A today announced the appointment of Robert J. Wills, Ph.D., to the Company's Board of Directors.A "Rob brings to CymaBay over 35 years of pharmaceutical experience, including preclinical and clinical research and development, business development and strategic partnering," said Harold Van Wart, President and Chief Executive Officer of CymaBay. "As we continue to advance our two differentiated clinical assets, arfhalofenate in gout and MBX-8025 in high unmet need and orphan diseases, we expect his insight to be of significant value to the Company."


  14. National Lawsuit News: DePuy Claim Deadline ExtendedRead the original story w/Photo

    Tuesday Mar 24 | PRWeb

    A leading site for federal lawsuit news, provides timely news and information on product liability litigation and consumer safety lawsuits. According to a federal lawsuit news article on, DePuy Orthopaedics recently reached a new settlement to cover 1,400 more claimants who filed lawsuits nationwide for defective hip replacement parts.


  15. Soft Tissue Repair Market Trends, Growth Prospects To 2020: Grand View Research, Inc.Read the original story w/Photo

    Monday Mar 23 |

    The soft tissue repair market is expected to witness lucrative growth over the forecast period owing to the globally increasing geriatric population and increasing participation in soft tissue injury inducing sports. The increasing rate of obesity, rising awareness of soft tissue repair surgery and growing healthcare expenditure are the main drivers of this market.


  16. Akers Biosciences (AKER) Q4 2014 Results - Earnings Call TranscriptRead the original story w/Photo

    Monday Mar 23 | Seeking Alpha

    As a reminder, this conference is being recorded. I would now like to introduce your host for today's conference, Ben Simons with the Akers Investor Relations team.


  17. WSJ: The $8 Million Janitor's Approach to InvestingRead the original story w/Photo

    Monday Mar 23 | News Max

    You might have read last month on Newsmax Finance about Ronald Read, a Vermont gas station attendant and janitor, who died last June at the age of 92 with an $8 million fortune. A combination of frugality and wise investing helped propel him to that position.


  18. Eyeball Wars Heat Up In SenateRead the original story w/Photo

    Monday Mar 23 | CBS Local

    CBS4 CBS4 is now on It's the same great news, weather, and investigations you found on, but we've added a whole new range of great items and features to help you get more out [] My TV 33 My TV33 is now on


  19. Bottom LineRead the original story w/Photo

    Monday Mar 23 | The Hill

    HEALTHCARE. Marathon Pharmaceuticals registered an in-house lobbyist to work on various issues, including issues stemming from Food and Drug Administration regulations, drug development for rare diseases and pharmaceutical access and pricing issues.


  20. Contact lens pricing under debate in SpringfieldRead the original story w/Photo

    Monday Mar 23 | Chicago Tribune

    The Illinois legislature may consider a bill that would prohibit contact lens makers from setting price minimums. Nobody likes it when their contact lenses fall out.